ASCO GU 2022

Prostate Cancer

First-line treatment with olaparib significantly improves PFS in mCRPC

Presented By

Dr Fred Saad, Centre Hospitalier de l’Université de Montréal, Canada

Trial

Phase 3, PROpel

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:25

First-line treatment with niraparib significantly improves PFS in HRR-mutated mCRPC

Presented By

Dr Kim Chi, University of British Columbia, Canada

Trial

Phase 3, MAGNITUDE

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:25

Darolutamide improves OS in mHSPC

Presented By

Dr Matthew Smith, Massachusetts General Hospital Cancer Center, MA, USA

Trial

Phase 3, ARASENS

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:24

Continued enzalutamide plus docetaxel offers clinical benefit for mCRPC patients who progress on enzalutamide

Presented By

Dr Axel Merseburger, Universitätsklinikum Schleswig-Holstein, Germany

Trial

Phase 3, PRESIDE

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:24

Radiohybrid PSMA PET imaging has favourable detection rate for prostate cancer recurrence

Presented By

Dr David Schuster, Emory University School of Medicine, GA, USA

Trial

Phase 3, SPOTLIGHT

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:24

PSMA PET is a predictive biomarker in mCRPC progressing after docetaxel

Presented By

Prof. Michael Hofman, Peter MacCallum Cancer Centre, Australia

Trial

Phase 2, TheraP

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:23

Artificial intelligence improves prediction of long-term outcomes

Presented By

Dr Osama Mohamad, University of California San Francisco, CA, USA

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:22

Significant tumour response to neoadjuvant therapy in high-risk non-metastatic prostate cancer

Presented By

Prof. Neil Fleshner, Princess Margaret Cancer Centre, Canada

Trial

Phase 2, ACDC-RP

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:22

Addition of abiraterone to ADT/docetaxel does not increase bone loss

Presented By

Dr Guilhem Roubaud, Institut Bergonié, France

Trial

Phase 3, PEACE-1

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:21

Bavdegalutamide, a novel androgen receptor degrader, demonstrates clinical activity

Presented By

Dr Xin Gao, Massachusetts General Hospital, MA, USA

Trial

Phase 2, ARDENT

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:21

Urothelial Carcinoma

No benefit of olaparib in previously untreated, platinum-ineligible, metastatic urothelial carcinoma

Presented By

Dr Jonathan Rosenberg, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 2, BAYOU

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:19

Rucaparib maintenance therapy extends PFS in platinum-responsive metastatic urothelial carcinoma

Presented By

Dr Simon Crabb, University of Southampton, UK

Trial

Phase 2, ATLANTIS

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:18

Positive efficacy and safety of N-803 plus BCG infusion in BCG-unresponsive NMIBC

Presented By

Dr Sam Chang, Vanderbilt University Medical Center, TN, USA

Trial

Phase 3, QUILT-3.032

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:18

Adding lenvatinib to pembrolizumab does not improve survival in advanced urothelial carcinoma

Presented By

Dr Yohann Loriot, Institut Gustave Roussy, France

Trial

Phase 3, LEAP-011

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:18

Maintenance niraparib fails to improve PFS in advanced urothelial cancer

Presented By

Dr Francesca Vignani, Ordine Mauriziano Hospital, Italy

Trial

Phase 2, Meet-URO12

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:17

First-line avelumab shows clinical activity in advanced urothelial carcinoma

Presented By

Dr Roberto Iacovelli, Catholic University of Rome, Italy

Trial

Phase 2, ARIES

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:17

Favourable pathologic response rate with neoadjuvant chemotherapy in high-risk upper tract urothelial carcinoma

Presented By

Dr Wesley Yip, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 2

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:17

Second-line nivolumab/ipilimumab boost improves ORR in metastatic urothelial carcinoma

Presented By

Prof. Marc-Oliver Grimm, University Hospital Jena, Germany

Trial

Phase 2, TITAN-TCC

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:17

Sacituzumab govitecan effective in platinum-refractory metastatic urothelial cancer

Presented By

Dr Petros Grivas, University of Washington, WA, USA

Trial

Phase 2, TROPHY-U-01

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:16

Neoadjuvant enfortumab vedotin promising in MIBC ineligible for cisplatin

Presented By

Prof. Daniel Petrylak, Yale School of Medicine, CT, USA

Trial

Phase 1/2, EV-103

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:16

Renal Cell Carcinoma

High-risk early RCC may benefit from neoadjuvant avelumab plus axitinib

Presented By

Dr Axel Bex, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, NeoAvAx

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:14

DFS benefits with adjuvant pembrolizumab in RCC persist with longer follow-up

Presented By

Dr Toni Choueiri, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, KEYNOTE-564

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:14

Biomarkers predict response to immune nivolumab (± ipilimumab) in advanced RCC

Presented By

Dr Marc-Oliver Grimm, University Hospital Jena, Germany

Trial

Phase 2, TITAN-RCC

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:13

Combined nivolumab/axitinib treatment elicits good response in metastatic RCC

Presented By

Dr Matthew Zibelman, Fox Chase Cancer Center, PA, USA

Trial

Phase 1/2

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:13

Folliculin mutations not associated with sporadic chromophobe RCC

Presented By

Dr Joseph Jacob, Upstate University Hospital, NY, USA

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:13

Differential patterns of molecular alterations among sites of metastasis in RCC

Presented By

Dr Rana McKay, University of California San Diego, CA, USA

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:12

Nivolumab monotherapy represents an alternative first-line treatment option for treatment-naïve mRCC

Presented By

Dr Michael Atkins, Georgetown Lombardi Comprehensive Cancer Center, DC, USA

Trial

Phase 2, HCRN GU16-260

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:12

Penile & Testicular Cancer